What initial first-line systemic therapy would you generally recommend for an asymptomatic 60-year-old patient with ER-positive, HER2-positive breast cancer and documented liver and lung metastases who has received no prior therapy? The same patient but symptomatic?
Baselga J. Pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer (mBC) and clinical trials of the combination as adjuvant therapy for HER2-positive early-stage BC. Breast Cancer Update, Issue 2, 2013. Available at http://www.researchtopractice.com/browse-by-tumor-types/breast-cancer/5jcbe/12/2/jose%CC%81-baselga-md-phd/pertuzumab-combination-trastuzum.
Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19. Abstract
Gradishar WL. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol 2013;24(10):2492-500. Abstract
Miles D et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 2013;142(1):89-99. Abstract
Mohammed A et al. Targeted therapy for breast cancer. Am J Pathol 2013;183(4):1096-112. Abstract
Pritchard KI. Endocrine therapy: Is the first generation of targeted drugs the last? J Intern Med 2013;274(2):144-52. Abstract
Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461-71. Abstract
Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91. Abstract